US 2015/0307948 A1 · PROSTATE CANCER PROGNOSTIC COMPOSITIONS AND KITS

Abstract

Described herein are method, compositions and kits for prognosis of prostate cancer. The methods include determining the ratio of PCA3 and of a prostate-specific marker expression in a urine sample and correlating the value of the PCA3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject. The method for prognosing prostate cancer in a sample of a patient includes assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of prostate-specific marker in the sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of prostate-specific marker; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.

Claims20

Dependent claims

A method for treating prostate cancer in a patient comprising:

(a) obtaining a first urine sample from said patient;
(b) performing a first hybridization and/or amplification assay on mRNA or cDNA derived from said urine sample using at least a first oligonucleotide specific for a prostate cancer associated PCA3 RNA or cDNA;
(c) determining the amounts of:
(i) said prostate cancer associated PCA3 RNA or cDNA;
(ii) at least one further prostate cancer or neoplastic disease marker;
and
(iii) a prostate-specific marker,
in said urine sample;
(d) determining a first ratio value of said amount of said prostate cancer associated PCA3 RNA or cDNA and said amount of further prostate cancer or neoplastic disease marker over said amount of prostate-specific marker;
e) comparing said first ratio value to at least one predetermined cut-off value;
f) identifying said patient as having a more aggressive prostate cancer when the first ratio value is above said at least one predetermined cut-off value;
and
(g) administering to said patient a prostate cancer treatment for a more aggressive prostate cancer.

10 more elements

A method for treating prostate cancer in a patient comprising:

(a) obtaining a first urine sample from said patient;
(b) determining the amounts of:
(i) a prostate cancer associated PCA3 mRNA or cDNA molecule;
(ii) a prostate cancer or neoplastic disease marker;
and
(iii) a prostate-specific marker,
in a urine sample from said patient;
(c) normalizing the amounts of said PCA3 RNA or cDNA molecule and said prostate cancer or neoplastic disease marker to the amount of said prostate-specific marker;
and
(d) comparing said normalized amounts of said PCA3 RNA or cDNA molecule and said prostate cancer specific marker to at least one predetermined cut-off value;
(e) identifying said patient as having a more aggressive prostate cancer when said normalized amounts are above said at least one predetermined cut-off value;
and
(f) administering to said patient a prostate cancer treatment for a more aggressive prostate cancer.

10 more elements

A method for treating prostate cancer in a patient comprising:

(a) obtaining a first urine sample from said patient;
(b) determining the amounts of:
(i) a prostate cancer associated PCA3 RNA or cDNA molecule;
(ii) a prostate cancer or neoplastic disease marker;
and
(iii) a prostate-specific marker,
in a urine sample from said patient;
(c) normalizing the amounts of said PCA3 RNA molecule and said prostate cancer or neoplastic disease marker to the amount of said prostate-specific marker;
(d) repeating steps b) and c) using a second urine sample from said patient, wherein said second urine sample is obtained at a further point in time during therapy;
(e) comparing said normalized amounts of said PCA3 and of said prostate cancer or neoplastic disease marker in said first urine sample and said second urine sample;
(f) identifying said patient as having:
aa) a more aggressive prostate cancer, bb) prostate cancer progression, cc) a prostate cancer of a higher grade;
or dd) a prostate cancer of a higher stage, when said normalized amounts in said second urine sample obtained at a further point in time are above the normalized amounts of said first urine sample;
and
(g) administering to said patient a prostate cancer treatment for a more aggressive prostate cancer.

12 more elements

A method for treating prostate cancer in a patient comprising:

(a) obtaining a urine sample from said patient;
(b) performing a first hybridization and/or amplification assay on RNA or cDNA derived from said sample using at least a first oligonucleotide specific for a prostate cancer associated PCA3 RNA or cDNA;
(c) determining the amount of said prostate cancer associated PCA3 RNA or cDNA and the amount of a prostate-specific marker, in said urine sample;
(d) determining the presence or amount of a further prostate cancer or neoplastic disease marker in said urine sample;
(e) determining a first ratio value of said amount of said prostate cancer associated PCA3 mRNA or cDNA and said amount of further prostate cancer or neoplastic disease marker over said amount of prostate-specific marker;
(f) comparing said first ratio value to at least one predetermined cut-off value;
(g) identifying said patient as having a more aggressive prostate cancer when the first ratio value is above said at least one predetermined cut-off value;
(h) administering to said patient a prostate cancer treatment for a more aggressive prostate cancer.

5 more elements

Dependencies are inferred from the claim text.

Prostate cancer prognostic compositions and kits

Life of this patent

Prostate cancer prognostic compositions and kits

Life of this patent

Abstract

Claims20